Esperion Therapeutics (NASDAQ:ESPR) Share Price Passes Above Fifty Day Moving Average - Should You Sell?

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report)'s share price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.97 and traded as high as $1.04. Esperion Therapeutics shares last traded at $1.00, with a volume of 2,888,788 shares trading hands.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Tuesday, June 17th. The Goldman Sachs Group lowered their target price on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Finally, Needham & Company LLC reduced their price target on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Esperion Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $7.00.

Esperion Therapeutics Price Performance

The stock has a market capitalization of $227.93 million, a P/E ratio of -1.44 and a beta of 0.70. The stock's 50-day simple moving average is $0.97 and its 200 day simple moving average is $1.49.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The company had revenue of $65.00 million for the quarter, compared to the consensus estimate of $54.97 million. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 59.03%. As a group, analysts expect that Esperion Therapeutics, Inc. will post -0.29 earnings per share for the current fiscal year.

Institutional Trading of Esperion Therapeutics

Institutional investors have recently bought and sold shares of the company. Meridian Wealth Management LLC acquired a new stake in Esperion Therapeutics in the first quarter valued at approximately $29,000. Cibc World Markets Corp bought a new position in shares of Esperion Therapeutics in the fourth quarter valued at $39,000. Synergy Asset Management LLC grew its holdings in shares of Esperion Therapeutics by 3,496.3% during the first quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 30,138 shares during the last quarter. Private Advisor Group LLC raised its holdings in shares of Esperion Therapeutics by 33.2% in the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company's stock worth $58,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Crestline Management LP bought a new position in Esperion Therapeutics in the 4th quarter valued at about $63,000. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.